harrow
health
announce
third
quarter
financial
results
november
nashville
globe
newswire
harrow
health
nasdaq
hrow
today
announced
close
trading
monday
november
release
third
quarter
financial
results
host
conference
call
eastern
standard
time
pacific
standard
time
discuss
financial
results
recent
business
developments
close
market
november
harrow
issue
press
release
containing
link
third
quarter
letter
stockholders
letter
stockholders
archived
harrow
investor
relations
website
archives
section
along
preceding
letters
found
clicking
conference
call
primary
objective
allow
analysts
engage
question
answer
session
harrow
management
team
providing
brief
introduction
overview
quarter
outlook
business
conference
call
details
callers
international
callers
webcas
please
click
conference
call
replay
dial
replay
call
available
december
webcast
replay
available
february
callers
replay
id
replay
id
international
callers
replay
id
replay
id
webcast
please
click
harrow
health
harrow
health
nasdaq
hrow
owns
portfolio
healthcare
businesses
including
imprimisrx
nation
leading
ophthalmology
outsourcing
facility
pharmaceutical
compounding
business
company
holds
large
equity
positions
eton
pharmaceuticals
surface
pharmaceuticals
melt
pharmaceuticals
harrow
also
owns
mayfield
pharmaceuticals
stowe
pharmaceuticals
visionology
companies
founded
subsidiaries
harrow
health
company
also
owns
royalty
rights
certain
drug
candidates
developed
surface
melt
mayfield
harrow
intends
create
invest
grow
paradigm
shifting
healthcare
businesses
put
patients
first
information
harrow
health
please
visit
investor
relations
section
corporate
website
clicking
statements
press
release
contains
statements
within
meaning
private
securities
litigation
reform
act
statements
release
historical
facts
may
considered
statements
statements
based
management
current
expectations
subject
risks
uncertainties
may
cause
results
differ
materially
adversely
statements
contained
herein
potential
risks
uncertainties
could
cause
actual
results
differ
predicted
include
ability
make
commercially
available
compounded
formulations
technologies
timely
manner
physician
interest
prescribing
formulations
risks
related
compounding
pharmacy
operations
ability
enter
strategic
alliances
including
arrangements
pharmacies
physicians
healthcare
organizations
development
distribution
formulations
ability
obtain
intellectual
property
protection
assets
ability
accurately
estimate
expenses
cash
burn
raise
additional
funds
necessary
risks
related
research
development
activities
projected
size
potential
market
technologies
formulations
unexpected
new
data
safety
technical
issues
regulatory
market
developments
impacting
compounding
pharmacies
outsourcing
facilities
pharmaceutical
industry
competition
market
conditions
additional
risks
uncertainties
fully
described
harrow
health
filings
securities
exchange
commission
including
annual
report
form
quarterly
reports
form
documents
may
read
free
charge
sec
web
site
undue
reliance
placed
statements
speak
date
made
except
required
law
harrow
health
undertakes
obligation
update
statements
reflect
new
information
events
circumstances
date
made
reflect
occurrence
unanticipated
events
investor
contact
ir
